antibody | Freq | number_of_bleeds |
|---|---|---|
EJ | 3 | 11 |
JO1 | 42 | 119 |
MDA5 | 15 | 45 |
OJ | 2 | 5 |
PL12 | 11 | 25 |
PL7 | 6 | 16 |
Total | 79 | 221 |
longitudinal_report
All Longitundinal Bleeds
Longitudinal days are based on a bleed date, relative to a new medication start, within the following parameters:
- Bleed date between 0 to -180 days (-6 months) BEFORE a med start
- Farthest longitudinal follow-up date of 540 days (18 months) AFTER a med start
Longitudinal bleed data exists for the following antibodies:
Longitudinal Bleeds, Filtered
When filtering to require follow-up bleed dates that are:
- \(\pm\) 3 months away from ANY OF:
- 6 months after med start
- 12 month after med start
- 18 month after med start
here are the same results as above:
antibody | Freq | number_of_bleeds |
|---|---|---|
EJ | 2 | 8 |
JO1 | 30 | 75 |
MDA5 | 12 | 32 |
OJ | 1 | 2 |
PL12 | 8 | 19 |
PL7 | 5 | 12 |
Total | 58 | 148 |
Background Medication Data
Medication Details
Below are the numbers, by antibody, for patients on a background med (TRUE) or not (FALSE):
FALSE TRUE
EJ 0 2
JO1 13 17
MDA5 4 6
OJ 1 0
PL12 3 5
PL7 3 2
Looking at the individual medications of this cohort, you get:
Looking at medication breakdowns, we see:
T cell Medications
In total, 44 unique patients received T cell effector medications, with good longitudinal data.
antibody drugdesc long_date_index number
1 EJ AZATHIOPRINE 0 1
2 EJ AZATHIOPRINE 180 1
3 EJ AZATHIOPRINE 540 1
4 EJ METHOTREXATE 0 2
5 EJ METHOTREXATE 180 2
6 EJ METHOTREXATE 540 2
7 EJ PREDNISONE 0 3
8 EJ PREDNISONE 180 1
9 EJ PREDNISONE 360 2
10 EJ PREDNISONE 540 1
11 JO1 AZATHIOPRINE 0 10
12 JO1 AZATHIOPRINE 180 7
13 JO1 AZATHIOPRINE 360 4
14 JO1 AZATHIOPRINE 540 1
15 JO1 METHOTREXATE 0 8
16 JO1 METHOTREXATE 180 7
17 JO1 METHOTREXATE 360 3
18 JO1 METHOTREXATE 540 1
19 JO1 MYCOPHENOLATE MOFETIL 0 6
20 JO1 MYCOPHENOLATE MOFETIL 180 4
21 JO1 MYCOPHENOLATE MOFETIL 360 2
22 JO1 PREDNISONE 0 2
23 JO1 PREDNISONE 180 1
24 JO1 PREDNISONE 360 1
25 MDA5 AZATHIOPRINE 0 4
26 MDA5 AZATHIOPRINE 180 3
27 MDA5 AZATHIOPRINE 540 3
28 MDA5 METHOTREXATE 0 1
29 MDA5 METHOTREXATE 540 1
30 MDA5 METHYLPREDNISOLONE 0 1
31 MDA5 METHYLPREDNISOLONE 360 1
32 MDA5 MYCOPHENOLATE MOFETIL 0 5
33 MDA5 MYCOPHENOLATE MOFETIL 180 4
34 MDA5 MYCOPHENOLATE MOFETIL 360 3
35 PL12 AZATHIOPRINE 0 2
36 PL12 AZATHIOPRINE 180 2
37 PL12 AZATHIOPRINE 360 1
38 PL12 MYCOPHENOLATE MOFETIL 0 2
39 PL12 MYCOPHENOLATE MOFETIL 180 1
40 PL12 MYCOPHENOLATE MOFETIL 360 1
41 PL12 PREDNISONE 0 2
42 PL12 PREDNISONE 360 2
43 PL7 MYCOPHENOLATE MOFETIL 0 1
44 PL7 MYCOPHENOLATE MOFETIL 540 1
B Cell Medications / Other
In total, 26 unique patients received B cell effector medications, with good longitudinal data.
antibody drugdesc long_date_index number
1 EJ HUMAN IMMUNOGLOBULIN G 0 2
2 EJ HUMAN IMMUNOGLOBULIN G 180 2
3 EJ HUMAN IMMUNOGLOBULIN G 540 1
7 JO1 HUMAN IMMUNOGLOBULIN G 0 7
8 JO1 HUMAN IMMUNOGLOBULIN G 180 4
9 JO1 HUMAN IMMUNOGLOBULIN G 360 4
17 JO1 RITUXIMAB 0 3
18 JO1 RITUXIMAB 180 1
19 JO1 RITUXIMAB 360 1
20 JO1 RITUXIMAB 540 1
25 MDA5 HUMAN IMMUNOGLOBULIN G 0 3
26 MDA5 HUMAN IMMUNOGLOBULIN G 180 2
27 MDA5 HUMAN IMMUNOGLOBULIN G 360 1
28 MDA5 RITUXIMAB 0 2
29 MDA5 RITUXIMAB 360 2
35 OJ HUMAN IMMUNOGLOBULIN G 0 1
36 OJ HUMAN IMMUNOGLOBULIN G 360 1
40 PL12 RITUXIMAB 0 1
41 PL12 RITUXIMAB 180 1
42 PL12 RITUXIMAB 540 1
45 PL7 HUMAN IMMUNOGLOBULIN G 0 1
46 PL7 HUMAN IMMUNOGLOBULIN G 180 1
47 PL7 RITUXIMAB 0 4
48 PL7 RITUXIMAB 180 3
49 PL7 RITUXIMAB 360 1
50 PL7 RITUXIMAB 540 2
Other Medications
antibody drugdesc long_date_index number
1 JO1 ETANERCEPT 0 1
2 JO1 ETANERCEPT 180 1
3 JO1 ETANERCEPT 360 1
4 JO1 HYDROXYCHLOROQUINE SULFATE 0 1
5 JO1 HYDROXYCHLOROQUINE SULFATE 360 1
6 JO1 INFLIXIMAB 0 2
7 JO1 INFLIXIMAB 180 1
8 JO1 INFLIXIMAB 360 1
9 JO1 OTHER 0 1
10 JO1 OTHER 180 1
11 JO1 SULFASALAZINE 0 1
12 JO1 SULFASALAZINE 180 1
13 JO1 TOFACITINIB CITRATE 0 1
14 JO1 TOFACITINIB CITRATE 180 1
15 MDA5 TACROLIMUS 0 2
16 MDA5 TACROLIMUS 180 1
17 MDA5 TACROLIMUS 360 1
18 MDA5 TOFACITINIB CITRATE 0 1
19 MDA5 TOFACITINIB CITRATE 540 1
20 PL12 HYDROXYCHLOROQUINE SULFATE 0 2
21 PL12 HYDROXYCHLOROQUINE SULFATE 180 1
22 PL12 HYDROXYCHLOROQUINE SULFATE 360 2
23 PL12 TOCILIZUMAB 0 1
24 PL12 TOCILIZUMAB 180 1
Limited to B and T Cell Meds
Here are the results of the above transformations if you ONLY include “of-interest” T cell and B cell effector medications.
For example, this list EXCLUDES bleeds for all medications seen in Section 3.2.
Combined B and T Cell Meds
antibody | Freq | number_of_bleeds |
|---|---|---|
EJ | 2 | 8 |
JO1 | 26 | 64 |
MDA5 | 10 | 26 |
OJ | 1 | 2 |
PL12 | 6 | 14 |
PL7 | 5 | 12 |
Total | 50 | 126 |
T Cell Meds Only
antibody | Freq | number_of_bleeds |
|---|---|---|
EJ | 2 | 7 |
JO1 | 22 | 51 |
MDA5 | 8 | 20 |
PL12 | 5 | 11 |
PL7 | 1 | 2 |
Total | 38 | 91 |
B Cell Meds Only
antibody | Freq | number_of_bleeds |
|---|---|---|
EJ | 1 | 3 |
JO1 | 7 | 17 |
MDA5 | 4 | 8 |
OJ | 1 | 2 |
PL12 | 1 | 3 |
PL7 | 4 | 10 |
Total | 18 | 43 |
Medications by Antibody and Time
T Cell Medications
antibody drugdesc long_date_index number
1 EJ AZATHIOPRINE 0 1
2 EJ AZATHIOPRINE 180 1
3 EJ AZATHIOPRINE 540 1
4 EJ METHOTREXATE 0 2
5 EJ METHOTREXATE 180 2
6 EJ METHOTREXATE 540 2
7 EJ PREDNISONE 0 3
8 EJ PREDNISONE 180 1
9 EJ PREDNISONE 360 2
10 EJ PREDNISONE 540 1
antibody drugdesc long_date_index number
1 JO1 AZATHIOPRINE 0 10
2 JO1 AZATHIOPRINE 180 7
3 JO1 AZATHIOPRINE 360 4
4 JO1 AZATHIOPRINE 540 1
5 JO1 METHOTREXATE 0 8
6 JO1 METHOTREXATE 180 7
7 JO1 METHOTREXATE 360 3
8 JO1 METHOTREXATE 540 1
9 JO1 MYCOPHENOLATE MOFETIL 0 6
10 JO1 MYCOPHENOLATE MOFETIL 180 4
11 JO1 MYCOPHENOLATE MOFETIL 360 2
12 JO1 PREDNISONE 0 2
13 JO1 PREDNISONE 180 1
14 JO1 PREDNISONE 360 1
antibody drugdesc long_date_index number
1 PL7 MYCOPHENOLATE MOFETIL 0 1
2 PL7 MYCOPHENOLATE MOFETIL 540 1
antibody drugdesc long_date_index number
1 PL12 AZATHIOPRINE 0 2
2 PL12 AZATHIOPRINE 180 2
3 PL12 AZATHIOPRINE 360 1
4 PL12 MYCOPHENOLATE MOFETIL 0 2
5 PL12 MYCOPHENOLATE MOFETIL 180 1
6 PL12 MYCOPHENOLATE MOFETIL 360 1
7 PL12 PREDNISONE 0 2
8 PL12 PREDNISONE 360 2
antibody drugdesc long_date_index number
1 MDA5 AZATHIOPRINE 0 4
2 MDA5 AZATHIOPRINE 180 3
3 MDA5 AZATHIOPRINE 540 3
4 MDA5 METHOTREXATE 0 1
5 MDA5 METHOTREXATE 540 1
6 MDA5 METHYLPREDNISOLONE 0 1
7 MDA5 METHYLPREDNISOLONE 360 1
8 MDA5 MYCOPHENOLATE MOFETIL 0 5
9 MDA5 MYCOPHENOLATE MOFETIL 180 4
10 MDA5 MYCOPHENOLATE MOFETIL 360 3
B Cell Medications
antibody drugdesc long_date_index number
1 EJ HUMAN IMMUNOGLOBULIN G 0 2
2 EJ HUMAN IMMUNOGLOBULIN G 180 2
3 EJ HUMAN IMMUNOGLOBULIN G 540 1
antibody drugdesc long_date_index number
1 OJ HUMAN IMMUNOGLOBULIN G 0 1
2 OJ HUMAN IMMUNOGLOBULIN G 360 1
antibody drugdesc long_date_index number
1 JO1 HUMAN IMMUNOGLOBULIN G 0 7
2 JO1 HUMAN IMMUNOGLOBULIN G 180 4
3 JO1 HUMAN IMMUNOGLOBULIN G 360 4
4 JO1 RITUXIMAB 0 3
5 JO1 RITUXIMAB 180 1
6 JO1 RITUXIMAB 360 1
7 JO1 RITUXIMAB 540 1
antibody drugdesc long_date_index number
1 PL7 HUMAN IMMUNOGLOBULIN G 0 1
2 PL7 HUMAN IMMUNOGLOBULIN G 180 1
3 PL7 RITUXIMAB 0 4
4 PL7 RITUXIMAB 180 3
5 PL7 RITUXIMAB 360 1
6 PL7 RITUXIMAB 540 2
antibody drugdesc long_date_index number
1 PL12 RITUXIMAB 0 1
2 PL12 RITUXIMAB 180 1
3 PL12 RITUXIMAB 540 1
antibody drugdesc long_date_index number
1 MDA5 HUMAN IMMUNOGLOBULIN G 0 3
2 MDA5 HUMAN IMMUNOGLOBULIN G 180 2
3 MDA5 HUMAN IMMUNOGLOBULIN G 360 1
4 MDA5 RITUXIMAB 0 2
5 MDA5 RITUXIMAB 360 2
Other Medications
antibody drugdesc long_date_index number
1 JO1 ETANERCEPT 0 1
2 JO1 ETANERCEPT 180 1
3 JO1 ETANERCEPT 360 1
4 JO1 HYDROXYCHLOROQUINE SULFATE 0 1
5 JO1 HYDROXYCHLOROQUINE SULFATE 360 1
6 JO1 INFLIXIMAB 0 2
7 JO1 INFLIXIMAB 180 1
8 JO1 INFLIXIMAB 360 1
9 JO1 OTHER 0 1
10 JO1 OTHER 180 1
11 JO1 SULFASALAZINE 0 1
12 JO1 SULFASALAZINE 180 1
13 JO1 TOFACITINIB CITRATE 0 1
14 JO1 TOFACITINIB CITRATE 180 1
antibody drugdesc long_date_index number
1 PL12 HYDROXYCHLOROQUINE SULFATE 0 2
2 PL12 HYDROXYCHLOROQUINE SULFATE 180 1
3 PL12 HYDROXYCHLOROQUINE SULFATE 360 2
4 PL12 TOCILIZUMAB 0 1
5 PL12 TOCILIZUMAB 180 1
antibody drugdesc long_date_index number
1 MDA5 TACROLIMUS 0 2
2 MDA5 TACROLIMUS 180 1
3 MDA5 TACROLIMUS 360 1
4 MDA5 TOFACITINIB CITRATE 0 1
5 MDA5 TOFACITINIB CITRATE 540 1
Candidates for Proteomics
drugdesc | 0 | 180 | 360 | 540 | Total |
|---|---|---|---|---|---|
AZATHIOPRINE | 17 (42.5%) | 13 (32.5%) | 5 (12.5%) | 5 (12.5%) | 40 (100.0%) |
HUMAN IMMUNOGLOBULIN G | 14 (46.7%) | 9 (30.0%) | 6 (20.0%) | 1 (3.3%) | 30 (100.0%) |
METHYLPREDNISOLONE | 1 (50.0%) | 0 (0.0%) | 1 (50.0%) | 0 (0.0%) | 2 (100.0%) |
MYCOPHENOLATE MOFETIL | 14 (46.7%) | 9 (30.0%) | 6 (20.0%) | 1 (3.3%) | 30 (100.0%) |
PREDNISONE | 7 (46.7%) | 2 (13.3%) | 5 (33.3%) | 1 (6.7%) | 15 (100.0%) |
RITUXIMAB | 10 (43.5%) | 5 (21.7%) | 4 (17.4%) | 4 (17.4%) | 23 (100.0%) |
Total | 63 (45.0%) | 38 (27.1%) | 27 (19.3%) | 12 (8.6%) | 140 (100.0%) |
Given the above, it seems reasonable to remove entries for:
- methprednisolone
- prednisone
drugdesc | 0 | 180 | 360 | 540 | Total |
|---|---|---|---|---|---|
AZATHIOPRINE | 17 (42.5%) | 13 (32.5%) | 5 (12.5%) | 5 (12.5%) | 40 (100.0%) |
HUMAN IMMUNOGLOBULIN G | 14 (46.7%) | 9 (30.0%) | 6 (20.0%) | 1 (3.3%) | 30 (100.0%) |
MYCOPHENOLATE MOFETIL | 14 (46.7%) | 9 (30.0%) | 6 (20.0%) | 1 (3.3%) | 30 (100.0%) |
RITUXIMAB | 10 (43.5%) | 5 (21.7%) | 4 (17.4%) | 4 (17.4%) | 23 (100.0%) |
Total | 55 (44.7%) | 36 (29.3%) | 21 (17.1%) | 11 (8.9%) | 123 (100.0%) |
Now when looking at the antibody breakdown, also by longitudinal dates:
$AZATHIOPRINE
antibody 0 180 360 540 Total
EJ 1 (33.3%) 1 (33.3%) 0 (0.0%) 1 (33.3%) 3 (100.0%)
JO1 10 (45.5%) 7 (31.8%) 4 (18.2%) 1 (4.5%) 22 (100.0%)
MDA5 4 (40.0%) 3 (30.0%) 0 (0.0%) 3 (30.0%) 10 (100.0%)
OJ 0 (-) 0 (-) 0 (-) 0 (-) 0 (100.0%)
PL12 2 (40.0%) 2 (40.0%) 1 (20.0%) 0 (0.0%) 5 (100.0%)
PL7 0 (-) 0 (-) 0 (-) 0 (-) 0 (100.0%)
Total 17 (42.5%) 13 (32.5%) 5 (12.5%) 5 (12.5%) 40 (100.0%)
$`HUMAN IMMUNOGLOBULIN G`
antibody 0 180 360 540 Total
EJ 2 (40.0%) 2 (40.0%) 0 (0.0%) 1 (20.0%) 5 (100.0%)
JO1 7 (46.7%) 4 (26.7%) 4 (26.7%) 0 (0.0%) 15 (100.0%)
MDA5 3 (50.0%) 2 (33.3%) 1 (16.7%) 0 (0.0%) 6 (100.0%)
OJ 1 (50.0%) 0 (0.0%) 1 (50.0%) 0 (0.0%) 2 (100.0%)
PL12 0 (-) 0 (-) 0 (-) 0 (-) 0 (100.0%)
PL7 1 (50.0%) 1 (50.0%) 0 (0.0%) 0 (0.0%) 2 (100.0%)
Total 14 (46.7%) 9 (30.0%) 6 (20.0%) 1 (3.3%) 30 (100.0%)
$`MYCOPHENOLATE MOFETIL`
antibody 0 180 360 540 Total
EJ 0 (-) 0 (-) 0 (-) 0 (-) 0 (100.0%)
JO1 6 (50.0%) 4 (33.3%) 2 (16.7%) 0 (0.0%) 12 (100.0%)
MDA5 5 (41.7%) 4 (33.3%) 3 (25.0%) 0 (0.0%) 12 (100.0%)
OJ 0 (-) 0 (-) 0 (-) 0 (-) 0 (100.0%)
PL12 2 (50.0%) 1 (25.0%) 1 (25.0%) 0 (0.0%) 4 (100.0%)
PL7 1 (50.0%) 0 (0.0%) 0 (0.0%) 1 (50.0%) 2 (100.0%)
Total 14 (46.7%) 9 (30.0%) 6 (20.0%) 1 (3.3%) 30 (100.0%)
$RITUXIMAB
antibody 0 180 360 540 Total
EJ 0 (-) 0 (-) 0 (-) 0 (-) 0 (100.0%)
JO1 3 (50.0%) 1 (16.7%) 1 (16.7%) 1 (16.7%) 6 (100.0%)
MDA5 2 (50.0%) 0 (0.0%) 2 (50.0%) 0 (0.0%) 4 (100.0%)
OJ 0 (-) 0 (-) 0 (-) 0 (-) 0 (100.0%)
PL12 1 (33.3%) 1 (33.3%) 0 (0.0%) 1 (33.3%) 3 (100.0%)
PL7 4 (40.0%) 3 (30.0%) 1 (10.0%) 2 (20.0%) 10 (100.0%)
Total 10 (43.5%) 5 (21.7%) 4 (17.4%) 4 (17.4%) 23 (100.0%)Some of the bleed numbers, especially for antibodies other than JO1 or MDA5, are sparse (e.g., some antibodies only have one patient getting a medication each).
For Azathioprine
- EJ patients: n = 1
- PL12 patients: n = 2
If we remove these, we get:
antibody | 0 | 180 | 360 | 540 | Total |
|---|---|---|---|---|---|
EJ | 1 (33.3%) | 1 (33.3%) | 0 (0.0%) | 1 (33.3%) | 3 (100.0%) |
JO1 | 10 (45.5%) | 7 (31.8%) | 4 (18.2%) | 1 (4.5%) | 22 (100.0%) |
MDA5 | 4 (40.0%) | 3 (30.0%) | 0 (0.0%) | 3 (30.0%) | 10 (100.0%) |
PL12 | 2 (40.0%) | 2 (40.0%) | 1 (20.0%) | 0 (0.0%) | 5 (100.0%) |
Total | 17 (42.5%) | 13 (32.5%) | 5 (12.5%) | 5 (12.5%) | 40 (100.0%) |
For Mycophenolate Mofetil
Follow up numbers, while modest for MMF, often have multiple data points. The exception is EJ and PL7:
- EJ patients: n = 0
- PL7 patients: n = 1, with just a day 0 and day 540 f/u
If removing those, we get:
antibody | 0 | 180 | 360 | Total |
|---|---|---|---|---|
JO1 | 6 (50.0%) | 4 (33.3%) | 2 (16.7%) | 12 (100.0%) |
MDA5 | 5 (41.7%) | 4 (33.3%) | 3 (25.0%) | 12 (100.0%) |
PL12 | 2 (50.0%) | 1 (25.0%) | 1 (25.0%) | 4 (100.0%) |
Total | 13 (46.4%) | 9 (32.1%) | 6 (21.4%) | 28 (100.0%) |
B Cell Meds
For IVIG
Bleed numbers by specific antibodies are also low here.
- OJ patients: n = 1
So if excluding OJ, we get:
antibody | 0 | 180 | 360 | 540 | Total |
|---|---|---|---|---|---|
EJ | 2 (40.0%) | 2 (40.0%) | 0 (0.0%) | 1 (20.0%) | 5 (100.0%) |
JO1 | 7 (46.7%) | 4 (26.7%) | 4 (26.7%) | 0 (0.0%) | 15 (100.0%) |
MDA5 | 3 (50.0%) | 2 (33.3%) | 1 (16.7%) | 0 (0.0%) | 6 (100.0%) |
PL7 | 1 (50.0%) | 1 (50.0%) | 0 (0.0%) | 0 (0.0%) | 2 (100.0%) |
Total | 13 (46.4%) | 9 (32.1%) | 5 (17.9%) | 1 (3.6%) | 28 (100.0%) |
For Rituximab
These is some complexity to the rituximab data.
- PL12 patients: n = 1
I propose keeping all samples, since the PL12 patient above has n = 3 total bleeds.
antibody | 0 | 180 | 360 | 540 | Total |
|---|---|---|---|---|---|
JO1 | 3 (13.0%) | 1 (4.3%) | 1 (4.3%) | 1 (4.3%) | 6 (26.1%) |
MDA5 | 2 (8.7%) | 0 (0.0%) | 2 (8.7%) | 0 (0.0%) | 4 (17.4%) |
PL12 | 1 (4.3%) | 1 (4.3%) | 0 (0.0%) | 1 (4.3%) | 3 (13.0%) |
PL7 | 4 (17.4%) | 3 (13.0%) | 1 (4.3%) | 2 (8.7%) | 10 (43.5%) |
Total | 10 (43.5%) | 5 (21.7%) | 4 (17.4%) | 4 (17.4%) | 23 (100.0%) |
Hand-Vetted Exclusions
After looking up the ILD statuses in EPIC of the patients above, a small group showed inconsistencies with their titer-based antibody diagnoses (what we are using here) and what their clinical diagnosis in the chart holds.
Thus, we propose excluding the following patients:
antibody | MYCOPHENOLATE MOFETIL | RITUXIMAB | Total |
|---|---|---|---|
MDA5 | 2 | 0 | 2 |
PL12 | 2 | 3 | 5 |
Total | 4 | 3 | 7 |
antibody | 0 | 180 | 540 | Total |
|---|---|---|---|---|
MDA5 | 1 | 1 | 0 | 2 |
PL12 | 2 | 2 | 1 | 5 |
Total | 3 | 3 | 1 | 7 |
Overall Proposed Proteomics Dataset
N = 37 unique patients
N = 90 total bleeds
n = 2 / 37 EJ patients
n = 20 / 37 JO1 patients
n = 8 / 37 MDA5 patients
n = 3 / 37 PL12 patients
n = 4 / 37 PL7 patientsantibody | Freq | number_of_bleeds |
|---|---|---|
EJ | 2 (5.4%) | 6 (6.7%) |
JO1 | 20 (54.1%) | 46 (51.1%) |
MDA5 | 8 (21.6%) | 21 (23.3%) |
PL12 | 3 (8.1%) | 7 (7.8%) |
PL7 | 4 (10.8%) | 10 (11.1%) |
Total | 37 (100.0%) | 90 (100.0%) |
antibody | AZATHIOPRINE | HUMAN IMMUNOGLOBULIN G | MYCOPHENOLATE MOFETIL | RITUXIMAB | Total |
|---|---|---|---|---|---|
EJ | 3 (2.7%) | 5 (4.5%) | 0 (0.0%) | 0 (0.0%) | 8 (7.1%) |
JO1 | 22 (19.6%) | 15 (13.4%) | 12 (10.7%) | 6 (5.4%) | 55 (49.1%) |
MDA5 | 10 (8.9%) | 6 (5.4%) | 10 (8.9%) | 4 (3.6%) | 30 (26.8%) |
PL12 | 5 (4.5%) | 0 (0.0%) | 2 (1.8%) | 0 (0.0%) | 7 (6.2%) |
PL7 | 0 (0.0%) | 2 (1.8%) | 0 (0.0%) | 10 (8.9%) | 12 (10.7%) |
Total | 40 (35.7%) | 28 (25.0%) | 24 (21.4%) | 20 (17.9%) | 112 (100.0%) |
Filter Out by Samples on hand at NIH
We already have n = 19 / 90 bleeds on hand.
Of that:
- n = 1 / 19 are from SOMA testing
- n = 18 / 19 are from other non-SOMA testing at the NIH
Thus, we need to request n = 71 / 90 samplesantibody | Freq | number_of_bleeds |
|---|---|---|
EJ | 2 | 6 |
JO1 | 20 | 34 |
MDA5 | 8 | 18 |
PL12 | 3 | 5 |
PL7 | 4 | 8 |
Total | 37 | 71 |